CML Risk Suite

EUTOS, ELTS, Sokal, Hasford in a single page. Pure HTML, CSS, and JS.

Baseline Inputs

years
cm
%
×10^9/L
%
%

All values are baseline at diagnosis. Platelets are expressed in ×10^9/L.

EUTOS

Score
0.0
7 × basophils + 4 × spleen
Risk
Low
Cutoff 87
5 year PFS, imatinib era
90.0%
CCyR at 18 months, by risk
86.0%
Predicted CCyR at 18 months
0.0%
Logistic model
x = exp(−2.1007 + 0.0700 × basophils + 0.0402 × spleen). Probability not achieving CCyR at 18 months = x ∕ (1 + x).

ELTS

Score
0.000
0.0025×(age/10)^3 + 0.0615×spleen + 0.1052×blasts + 0.4104×(platelets/1000)^(-0.5)
Risk
Low
Low ≤ 1.568, Intermediate ≤ 2.2185

Sokal

Index
0.000
exp(0.0116(A-43.4)+0.0345(S-7.51)+0.188(P/700-1)+0.0887(B-2.1))
Risk
Low
Low < 0.8, Intermediate ≤ 1.2

Hasford / Euro

Score
0
Composite ×1000 scaling
Risk
Low
Low < 780, Intermediate ≤ 1480

References

  • EUTOS: Hasford J, et al. Blood 2011. https://pubmed.ncbi.nlm.nih.gov/21527509/
  • ELTS: Pfirrmann M, et al. Blood 2016. https://pubmed.ncbi.nlm.nih.gov/27470620/
  • Sokal: Sokal JE, et al. Blood 1984. https://pubmed.ncbi.nlm.nih.gov/6589184/
  • Hasford: Hasford J, et al. JNCI 1998. https://pubmed.ncbi.nlm.nih.gov/9811310/

Important: EUTOS PFS and CCyR are imatinib era benchmarks. ELTS stratifies risk of CML related death. Sokal and Hasford survival estimates are historical and improve with modern TKI therapy. Exact percentages vary by cohort and treatment. Use with current guidelines and molecular monitoring.